Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial

Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19.Design Prospective, multicentre, double-blind, placebo-controlled trial.Setting Ten acu...

Full description

Bibliographic Details

Published in:	BMJ Open
Main Authors:	Mark Jones, Gagandeep Kang, Thomas L Snelling, Vivekanand Jha, Vinay Rathore, Stephane Heritier, Meg Jardine, Kapil Soni, James Totterdell, Sradha Kotwal, Guy Thwaites, Cheryl Jones, Carol Pollock, Richard Haynes, Katrina Diamante, Abhinav Bassi, Nikita Bathla, Natalie Staplin, Arlen Wilcox, Ashpak Bangi, Gregory Fox, Atul Jindal, Rui Xie, Daniel Vincent O'Hara, Sanjay D'Cruz, Manish Kumar Jain, Louise Burrell, Sharifah Faridah Syed Omar, Gerard Estivill Mercade, Aishwarya Nair, Annelise Decaria, Nicola Abignano, Sabah Siddiqui, Suprava Patel, Anjulata Sahu, Yasmeen Shaikh, Madhavender Jain, Shivam R Kanje, Sanjeev Kumar Vimal, K. Kalyan Chakravarthy, P. Sathish Babu, Yuvraj Singh Cheema, Merlin Moni, Sivapriya G Nair
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-10-01
Online Access:	https://bmjopen.bmj.com/content/14/10/e081790.full